CAJ | 학술논문

靶向识别特异抗原的嵌合抗原受体修饰T细胞(CAR-T细胞)已成为治疗恶性血液病的有效手段.临床研究涉及多种多样的CAR设计、不同的生产工艺及研究群体等.CAR-T细胞治疗慢性淋巴细胞白血病(CLL)和急性淋巴细胞白血病(ALL)已取得了令人瞩目的疗效,这将有可能改变所有类型血液系统恶性肿瘤的治疗模式.第56届美国血液学会(ASH)年会中关于CAR-T细胞的研究结果鼓舞了人们对这类新型治疗策略的信心.文章介绍CAR-T细胞治疗的临床研究结果和应用前景.虽然CAR-T细胞治疗恶性血液病还存在着许多有待解决的问题,但其治疗的高反应率促使开展了更多的临床研究.
파향식별특이항원적감합항원수체수식T세포(CAR-T세포)이성위치료악성혈액병적유효수단.림상연구섭급다충다양적CAR설계、불동적생산공예급연구군체등.CAR-T세포치료만성림파세포백혈병(CLL)화급성림파세포백혈병(ALL)이취득료령인촉목적료효,저장유가능개변소유류형혈액계통악성종류적치료모식.제56계미국혈액학회(ASH)년회중관우CAR-T세포적연구결과고무료인문대저류신형치료책략적신심.문장개소CAR-T세포치료적림상연구결과화응용전경.수연CAR-T세포치료악성혈액병환존재착허다유대해결적문제,단기치료적고반응솔촉사개전료경다적림상연구.
T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies.Various CAR designs,manufacturing processes,and study populations,among other variables,have been studied and reported in clinical trials.The accumulating data supporting CAR-T cells therapy for disease such as chronic lymphocytic leukemia (CLL)and acute lymphocytic leukemia (ALL) highlight what may well become the next sea change in the care of patients with all types of hematologic neoplasia.The scientific symposium on CAR-T cells therapy inspires the mounting enthusiasm regarding this new treatment strategy.Here,the results of the reported clinical trials and the outlook for CAR-T cells therapies were reviewed and discussed.Many questions remain in the field of CAR-T cells directed to hematologic malignancies,but the encouraging response rates pave a wide road for future investigation.